Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon M Blumenthal

Showing results (21-30 of 83) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Overestimation of the effect size in group sequential trialsJenny J Zhang, Gideon M Blumenthal, Kun He, et al.
The Oncologist|June 23, 2016
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung CancerDickran Kazandjian, Gideon M Blumenthal, Lola Luo, et al.
The Oncologist|June 4, 2017
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough TherapiesGideon M Blumenthal, Paul G Kluetz, Julie Schneider, et al.
Obstetrics and Gynecology|January 25, 2013
Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancerAsli Kalin, Melissa A Merideth, Debra S Regier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted TherapiesJulia A Beaver, Abraham Tzou, Gideon M Blumenthal, et al.
The Oncologist|November 29, 2017
Accelerating Early Access to Immunotherapies for Advanced Urothelial CarcinomaYang-Min Ning, V Ellen Maher, Julia A Beaver, et al.
Seminars in Oncology|November 5, 2018
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodiesShanthi Marur, Harpreet Singh, Pallavi Mishra-Kalyani, et al.
The Oncologist|July 28, 2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumorsGideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, et al.
The Oncologist|August 30, 2014
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangementsDickran Kazandjian, Gideon M Blumenthal, Huan-Yu Chen, et al.
The Oncologist|October 9, 2015
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based ChemotherapyErin Larkins, Barbara Scepura, Gideon M Blumenthal, et al.
Pageof 9

Showing results (21-30 of 83) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Overestimation of the effect size in group sequential trialsJenny J Zhang, Gideon M Blumenthal, Kun He, et al.
The Oncologist|June 23, 2016
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung CancerDickran Kazandjian, Gideon M Blumenthal, Lola Luo, et al.
The Oncologist|June 4, 2017
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough TherapiesGideon M Blumenthal, Paul G Kluetz, Julie Schneider, et al.
Obstetrics and Gynecology|January 25, 2013
Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancerAsli Kalin, Melissa A Merideth, Debra S Regier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted TherapiesJulia A Beaver, Abraham Tzou, Gideon M Blumenthal, et al.
The Oncologist|November 29, 2017
Accelerating Early Access to Immunotherapies for Advanced Urothelial CarcinomaYang-Min Ning, V Ellen Maher, Julia A Beaver, et al.
Seminars in Oncology|November 5, 2018
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodiesShanthi Marur, Harpreet Singh, Pallavi Mishra-Kalyani, et al.
The Oncologist|July 28, 2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumorsGideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, et al.
The Oncologist|August 30, 2014
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangementsDickran Kazandjian, Gideon M Blumenthal, Huan-Yu Chen, et al.
The Oncologist|October 9, 2015
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based ChemotherapyErin Larkins, Barbara Scepura, Gideon M Blumenthal, et al.
Pageof 9